


## Data Sheet

<b>Product Name:</b>	S1RA (hydrochloride)
<b>Cat. No.:</b>	CS-2188
<b>CAS No.:</b>	1265917-14-3
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>24</sub> CIN <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	373.88
<b>Target:</b>	Sigma Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Solubility:</b>	DMSO : ≥ 57 mg/mL (152.46 mM)



### BIOLOGICAL ACTIVITY:

S1RA hydrochloride (E-52862 hydrochloride) is a potent and selective sigma-1 receptor ( $\sigma$ 1R,  $K_i=17$  nM) antagonist, showed good selectivity against  $\sigma$ 2R ( $K_i > 1000$  nM). IC<sub>50</sub> value: 17 nM ( $K_i$ ) [1] Target:  $\sigma$ 1R antagonist in vitro: S1RA behaved as a highly selective  $\sigma$ 1 receptor antagonist. It showed high affinity for human ( $K_i= 17$  nM) and guinea pig ( $K_i= 23.5$  nM)  $\sigma$ 1 receptors but no significant affinity for the  $\sigma$ 2 receptors ( $K_i > 1000$  nM for guinea pig and rat  $\sigma$ 2 receptors). Moderate affinity ( $K_i= 328$  nM) and antagonistic activity, with very low potency (IC<sub>50</sub>= 4700 nM) was found at the human 5-HT<sub>2B</sub> receptor. S1RA showed no significant affinity ( $K_i > 1$   $\mu$ M or % inhibition at 1  $\mu$ M < 50%) for other additional 170 targets (receptors, transporters, ion channels and enzymes) [2]. in vivo: Control (non-operated) and nerve-injured mice received a single or repeated (twice daily for 12 days) i.p. administration of S1RA at 25 mg/kg 1, the same dose used for the assessment of behavioural hypersensitivity in the chronic treatment study. Acute treatment was given on day 12 post-surgery and repeated treatment with S1RA started the day of surgery, as in the behavioural studies [2]. Intrathecal pre-treatment with idazoxan prevented the systemic S1RA antinociceptive effect, suggesting that the S1RA antinociception depends on the activation of spinal  $\alpha$ 2 -adrenoceptors which, in turn, could induce an inhibition of formalin-evoked glutamate release. When administered locally, intrathecal S1RA inhibited only the flinching behavior, whereas intracerebroventricularly or intraplantarly injected also attenuated the lifting/licking behavior [3].

### References:

- [1]. Díaz JL, et al. Synthesis and biological evaluation of the 1-arylpyrazole class of  $\sigma$ (1) receptor antagonists: identification of 4-(2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yl]oxy)ethyl-morpholine (S1RA, E-52862). *J Med Chem.* 2012 Oct 11;55(19):8211-24.
- [2]. Romero L, et al. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. *Br J Pharmacol.* 2012 Aug;166(8):2289-306.
- [3]. Vidal-Torres A, et al. Effects of the selective sigma-1 receptor antagonist S1RA on formalin-induced pain behavior and neurotransmitter release in the spinal cord in rats. *J Neurochem.* 2014 Jan 3.

### CAIndexNames:

Morpholine, 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]-, hydrochloride (1:1)

### SMILES:

CC1=CC(OCCN2CCOCC2)=NN1C3=CC(C=CC=C4)=C4C=C3.[H]Cl

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA